Skip to main content
. 2019 Mar 24;10(3):136–148. doi: 10.5306/wjco.v10.i3.136

Figure 4.

Figure 4

Prolonged followup of patients reveals importance of variant fibroblast growth factor receptor 4 allele. A: Estimated disease-free survival of Head and Neck Squamous Cell Carinoma patients by fibroblast growth factor receptor 4 (FGFR4) genotype showing a reduced disease-free survival due to mutant FGFR4 Arg388 relative to wildtype FGFR4 Gly388 after two years of progression study; B: Estimated disease-free survival (disease progression) of HNSCC patients by FGFR4 genotype with the interactive effects of lymph node, recurrence and tumor status incorporated in the reduction of disease-free survival due to mutant FGFR4 Arg388 relative to the predominant FGFR4 Gly388 allele after two years of study.